with RA, but with a contribution of only one third of genetic susceptibility, 3 which indicates that additional genetic risk factors remain to be identified. 4, 5 Apart from the previously mentioned features, tobacco smoking is considered as the most important environmental factor for modifying RA by mediating oxidative stress associated with both susceptibility and severity to RA.
6
Inflammation is a central trait of RA occurring with the resulting reactive oxygen species (ROS), which cause oxidative damage to cellular molecules such as DNA and lipids, giving rise to a variety of cytotoxic products. 7 ROS are involved in RA as they are increasingly generated by phagocytes in the synovial fluid of inflamed joints during hypoxia-reperfusion events, and they cause DNA and lipid oxidation, leading to cartilage and bone destruction. The detoxification mechanism against ROS products is complex and requires several enzymes, namely, glutathione S-transferases (GST), which plays a key protective antioxidant role for cells against ROS aggression. 8 GSTs are multifunctional enzymes that play a pivotal function in the detoxification of varieties of both endogenous products of oxidative stress and exogenous carcinogens.
Glutathione S-transferase M1 (GSTM1) (OMIM 138350), a member of GST mu class cluster on the short arm of chromosome 1 (1p13.3), is highly polymorphic in human population. 9 The deletion of GSTM1 emerges by separate equal or unequal recombination events involving crossing-over between two highly homologous repeat regions that flank the gene. 10 These recombination events produce deletionjunction regions of several kilobases, which have very high homology (98%) to the flanking repeat regions, resulting in a complete lack of the gene, and thus in a deficient conjugating activity. 11 This homozygous deletion has been observed in different ethnic populations such as
Caucasians (48%-57%), African Americans (23%-41%), Asians (32%-53%), and Hispanics (40%-53%). 12 Although several studies have examined the contribution of null genotype of GSTM1 (0 copy) to RA susceptibility, they have produced conflicting results. [13] [14] [15] [16] [17] [18] [19] [20] [21] Copy number variations (CNVs) are large polymorphisms, such as deletions, insertions, translocations, and inversions of genomic material varying from 1 kilobase to several megabases. 22 CNVs are now recognized to be a prevalent form of common genetic variation and represent a substantial proportion of total genetic variability in human populations. Recent association studies have focused on the importance of CNVs as disease susceptibility variants to confer differential risk to common and autoimmune diseases such as RA. To the best of our knowledge, there have been very few studies on the association between CNVs of GSTM1 and RA. 16 This is due to the unreliability of available techniques. For instance, PCR multiplex and real-time quantitative PCR (qPCR) do not measure the absolute number of copies, which is a prerequisite for the meaningful analyses of association between CNVs and RA. Indeed, previous studies pertaining to the genetic association of GSTM1 have only focused on detecting ''null'' allele against ''positive'' allele. This study aims to investigate the association case-control study of GSTM1 CNVs with the development of RA in Tunisian population taking advantage of a recent system of quantification for dPCR analysis, the digital droplet PCR (ddPCR), 23 which provides an absolute quantification of target DNA at high levels of sensitivity and specificity for more precision and reliability in the estimation of the exact copies number of gene of interest.
| MATERIALS AND METHODS

| Participants
A total of 165 unrelated Tunisian RA patients were recruited into the study. All patients fulfilled the 1987 American College of Rheumatology (ACR) criteria for RA. 24 The clinical and laboratory characteristics of the patients with RA are summarized in Table 1 . The latter contains the following characteristics for each RA index: gender, presence of bone erosions at x-ray examination, rheumatoid nodules, other autoimmune diseases and HLA-DRB1 shared epitope alleles, as well as seropositivity for rheumatoid factor (RF) and for anti-cyclic citrullinated peptide antibodies (Anti-CCP). One hundred and two ethnically matched healthy blood donors were used as controls. They were free of any autoimmune or inflammatory diseases at blood sampling and originating from the same area as the RA sample. Samples were obtained from subjects (patients and controls) after they provided written informed consent. The study was approved by the local ethics committee of the Hedi Chaker University Hospital of Sfax, Tunisia.
| Molecular genotyping and determination of GSTM1 copy number
Genomic DNA from whole blood was obtained from peripheral blood leukocytes samples taken from each patient by standard methods. Presence of Nodules (n=81) 7 8.6
Carrying at least one HLA-DRB1 shared epitope allele (n=100) 62 62.0
Other autoimmune disease (AID) (n=144)
Other autoimmune diseases: Gougerot-Sjögren syndrome (SS), thyroid autoimmune diseases, and type 1 diabetes (TD1).
probe was used for the reference gene, RPP30 (OMIM: 606115; BioRad Laboratories), with two copies for normalization as described in a previous study. 26 A total of 20 μL of reaction volume was prepared with 20 ng of DNA template, primers, and probes with final concentrations of 900 and 250 nmol/L, respectively, and Droplet PCR Supermix of CutSmart ™ buffer, and qspH2O. A quantity of 20 ng of digest DNA was used for the ddPCR protocol described above.
| Autoantibody analysis
The sera of RA patients obtained at the time of diagnosis were examined for RF by nephelometry and for Anti-CCP by enzyme-linked immunosorbent assay (ELISA) (Anti-CCP ELISA (IgG) EUROIMMUN ® , Lübeck, Germany). 
| Statistical analysis
| RESULTS
| Characterization of GSTM1 CNVs in Tunisian population by digital droplet PCR
The analysis of 267 samples (165 patients with RA and 102 healthy controls) was carried out using the high-throughput digital droplet PCR for determining the absolute quantification of CNVs. Ten samples (8 patients and 2 controls) with missing data were excluded. The quantification of GSTM1 CN identified in our Tunisian sample was 0, 1, and 2 copies per diploid genome. The mean number of droplets analyzed for all samples ranged between 13 000 and 16 000 droplets.
A total of 2.55% of samples showed a GSTM1 CN value higher than 2.25. These samples were analyzed a second time with a digestion step using HaeIII enzyme, leading to a CN value close to two, thus, declining the hypothesis for the presence of three copies in tandem conformation.
The distribution of GSTM1 CN frequencies in cases is 54.1% for 0 copy, 37.6% for 1 copy and 8.3% for 2 copies; and in controls 52% for 0 copy, 41% for 1 copy and 7% for 2 copies. It is noteworthy to point that the deletion of GSTM1 (0 copy) (54.1% and 52%) has a high frequency in our case-control Tunisian sample compared with the rest of copies ( Table 2) .
We subsequently examined the association of GSTM1 CNVs with RA stratified according to clinical and immunological characteristics.
The obtained results showed a trend of association of GSTM1 CNVs with the subgroup of anti-CCP + , which lost significance after adjustment with Bonferroni correction (P=.05, P c =.25). Otherwise, no significant difference was revealed considering RF (P>.05). In addition, no significant association was detected considering AIDs, hand erosions,
or HLA-DRB1*04 alleles (P>.05) ( Table 3) .
Moreover, the comparison of patients carrying deletion of GSTM1 (0 and 1 copy) to those with 2 copies identified a significant association of deletion of GSTM1 with anti-CCP positivity (OR=4.16, CI 95% =[1. 17-14.7] , P=.01, P c =.05) ( Table 3 ). In addition,
we applied multivariable analysis using the binary logistic regression.
Our results confirmed the significant risk for anti-CCP subgroup adjusted and unadjusted with the rest of subgroups (OR=11. 
| DISCUSSION
The characterization of CNVs of candidate genes is an important area in the discovery of new genomic factors of complex diseases such as RA. The present study investigated the contribution of CNVs of GSTM1 gene in the susceptibility to RA and its characteristics in Tunisian population quantified by digital droplet PCR (ddPCR), the highest scalable and robust methodology for absolute measure and quantification of CNVs.
Previous studies have enumerated the technical difficulties and inaccuracy in the quantification of CNVs by qPCR. 27 In fact, by using standard real-time assays, the different events of CNVs (deletion or duplication) can be difficult for quantification, which can make systematic errors, leading to equivocal results with noninteger CN, while normalizing DNA concentrations used in standard samples and in taking cycle threshold (Ct) measurements. 28 The reproducibility and accuracy of the dPCR in CNV analysis were proven when comparing qPCR and dPCR. 29, 30 Furthermore, the measurement of CNVs by ddPCR is more precise given that nucleic acid concentrations are obtained without The quantified CN of GSTM1 gene was 0, 1, and 2 copies in our case-control Tunisian sample with a high frequency (54%) of the com- Interestingly, the major finding in our study is the characterization of GSTM1 CNVs association with patients seropositive for Anti-CCP.
The deletion of GSTM1 (0 copy or 1 copy) was associated with increasing risk for Anti-CCP positive RA (P c =.05). This was confirmed when we performed multivariable analysis using the binary logistic regression by pooling all subgroups tested (P anti-CCP =.032). Our observation does confirm earlier studies in Swedish EIRA (2426 incident RA cases and 1257 controls) and US cohorts. 16, 34 This result is important as these antibodies are specific for the disease and have a prognostic and pathogenic significance. We suggest that CNVs of GSTM1 gene had no effect in the susceptibility to RA, but may influence its severity as the deletion of the gene is associated with seropositivity for Anti-CCP antibodies in RA Tunisian patients.
The heterogeneity of results between our study and some others in the involvement of CN of GSTM1 in the pathogenesis of RA may be explained by the genetic background and/or environmental differences existing among populations as well as the low number of samples analyzed.
In conclusion, the use of ddPCR method allowed us to determine CN accurately and permits to precisely explore the role of CNVs of GSTM1 in RA. The performance of this method can allow the characterization of genotypes of CNVs and its transmission in familial-based studies of complex diseases. For future research works, it can be said that our findings should be replicated with large case-control and familial samples. University. We are grateful to RA patients and rheumatologists for their participation in this study.
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